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SDC, Table 1, Breakdown of organ recovery cost components 
Items Surgery, Anesthesia, 
     Intensive Care 
Logistics Imaging Biology Consumables 
      
Sub-items     
      
 Medical care staff Sterilization 2 EEG HLA Surgical kit 
 Permanent medical care Biomedical engineering + Serology + 
 Nursing staff Hygiene 1 AU Viral genome Preservation 
 Non-medical staff Vigilance + Serology checkup fluid (IGL) 
 Maintenance  1 TR Hematology checkup  
 Depreciation and cost of block 
occupation 
  Serum electrolytes  
   Or ABO Blood-group  
    Blood gas analysis  
   1 CA Renal, liver, pancreas   
   + and cardiac checkup   
   1 TAP Scan   
      
 
EEG: Electroencephalography   CA: Cerebral Angioscanner 
AU: Abdominal Ultrasonography   TAP Scanner: Thoraco Abdomino Pelvien Scanner 
TR: Thoracic Radiography  
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SDC, Table 2, Cost of surgical kit for kidney recovery in the HCL (2011 Euros) 
 
 
 
 
 
 
 
 
 
 
 
 
Identification 
 
Quantification 
 
                  Valuation 
Unit Cost (€)        Cost by surgical kit (€) 
Sterile jars           2         57                               114  
Y-tube           2 1,31                             2,62 
PLDS self-suture clamp           1      156                               156 
TA 90 self-suture clamp           1      149                               149  
GIA 80 self-suture clamp               1      149                               149  
Refill GIA 80 self-suture clamp           1      118                               118  
Refill TA 90 self-suture clamp           1        95                                 95  
Standard clip applier           1        59                                 59 
 
 
Short clip applier            1        59                                 59  
Bard canulas            4        40                               160  
Powder compact           4 0,04                             0,16  
Biconical fitting           2  0,37                             0,74  
IGL (2L ; fluid preservation)           4       364                             1455  
   
TOTAL                                           2,516   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 46 
 
SDC, Table 3, Cost of surgical kit for pancreas recovery in the HCL (2011 Euros) 
  
Identification 
 
Quantification 
 
                  Valuation 
Unit Cost (€)        Cost by surgical kit (€) 
Sterile jars           2         57                               114  
Y-tube           2 1,31                             2,62 
PLDS self-suture clamp           1      156                               156 
TA 90 self-suture clamp           1      149                               149  
GIA 80 self-suture clamp               1      149                               149  
Refill GIA 80 self-suture clamp           1      118                               118  
Refill TA 90 self-suture clamp           1        95                                 95  
Standard clip applier           1        59                                 59 
 
 
Short clip applier            1        59                                 59  
Bard canulas            4        40                               160  
Powder compact           4 0,04                             0,16  
Biconical fitting           2  0,37                             0,74  
IGL (2L ; fluid preservation)           1       364                              364  
   
TOTAL                                             894   
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SDC, Table 4, Cost of surgical kit for liver recovery in the HCL (2011 Euros) 
 
Identification 
 
Quantification 
 
                  Valuation 
Unit Cost (€)        Cost by surgical kit (€) 
Iced saline bag          10         7                                   70 
Small bag           5      5,7                               28,5 
Y-tube           4      2,3                                 9,2  
Venous cannula Ch 12           2       16                                  32  
Venous cannula Ch 14           2       16                                  32  
Venous cannula Ch 16           2       16                                  32  
Venous cannula Ch 22           2       16                                  32 
 
 
Venous cannula Ch 28           2       16                                  32  
Pediatric umbilical catheter           2         4                                    8  
GIA Blue 80           1     138                                138  
Gia Refills 80 blue           3      98,5                                295  
Drain transcystic Ch 4           1    9,5                                9,5  
Drain transcystic Ch 5           2 9,5                                  19 
Drain transcystic Ch 6           2 9,5                                  19 
Drain transcystic Ch 7           1 9,5                                 9,5 
Clip M           1       61                                  61 
Clip S           1       49                                  49 
Powder box ECBU           3 0,05                            0,15 
Portagerm           3 1,3                                 3,9 
EDTA Tube           3 0,06                             0,18 
IGL (2L ; preservation fluid) 
 
          1      364                               364 
TOTAL                                          1,244 
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SDC, Table 5, Organs recovered in the HCL from January 2010 to December 2011 
 
 Organs removed Donors after Brain Death N° of organs  
 
1 organ removed 
 
   
 Kidneys alone   23          23 
 Liver alone    5 5 
 Pancreas alone    0 0 
 Other    1 1 
    
2 organs removed 
 
   
 Kidneys +Liver   27          54 
 Kidneys + Pancreas    1 2 
 Kidneys +Other     1 2 
 Other combination    0 0 
    
3 or more organs removed  
 
   
 Kidneys + Liver + Pancreas + Other(s)   23 89 
 Other combination   10 31 
    
 
Total 
  
  91 
      
        207 
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Appendix 2. Breakdown of cost components 
 
 
Items Sub-items 
Surgery 
- Medical staff 
- Non-medical staff 
- Nursing staff 
- Maintenance 
- Depreciation and cost of structure 
occupation 
Anaesthesia 
Reanimation 
Intensive care 
Ongoing monitoring 
Biology 
Imaging 
Medical logistics 
- Sterilisation 
- Biomedical engineering  
- Hygiene 
- Vigilance  
- Pharmacy 
 
 
 
Organ(s) recovered Codes 
Pancreas HNFA009  
Kidneys 
JAFA017 
JAFA018 
JAFA020 
Liver 
HLFA001 
HLFA008 
HLFA016 
Heart 
DZFA001 
DZFA002 
Block heart-lung DZFA003 
Lung GFFA020 
Intestine HGFA002 
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Abstract 
Background: The choice of cost data sources is crucial, influencing the results of cost studies, 
decisions of hospital managers and ultimately national directives of policymakers. 
The main objective of this study was to compare a hospital cost accounting system in a 
French hospital group and the national cost study (ENC) considering the cost of organ 
recovery procedures. The secondary objective was to compare these approaches to the 
weighting method used in the ENC to assess organ recovery costs. 
Methods: The resources consumed during the hospital stay and organ recovery procedure 
were identified and quantified retrospectively from hospital discharge abstracts and the 
national discharge abstract database. Items identified were valued using hospital cost 
accounting, followed by 2010-2011 ENC data and then weighted 2010-2011 ENC data. A 
Kruskal-Wallis test was used to detect whether at least two of the cost databases provide 
different results. Then, a Mann-Whitney test was used to compare the three cost databases. 
Results: The costs assessed using hospital cost accounting differ significantly from those 
obtained using ENC data (Mann-Whitney; P-value < 0.001). In the ENC, the mean costs for 
hospital stays and organ recovery procedures were assessed as 4 961€ (SD €7,295) and 862€ 
(SD €887), respectively, versus 12 074€ (SD €6,956) and €4,311 (SD €1,738) in the hospital 
cost accounting assessment. The use of a weighted methodology reduces the differences 
observed between these two data sources. 
Conclusions: Readers, hospital managers and decision-makers must know the strengths and 
weaknesses of each database to interpret the results in an informed context. 
Keywords: cost data source, hospital cost accounting, national cost study, organ recovery 
Background 
 The choice of cost data source is important because, as demonstrated in the case of 
colorectal cancer, using different data sources can produce widely different estimates of 
health care costs [1,2]. Currently, in a context of budget restrictions and trends toward more 
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efficiency in resource allocation, choosing the most appropriate cost database for medico-
economic evaluations appears to be a crucial determinant insofar as this choice influences not 
only the results of cost studies but also the decisions of hospital managers and ultimately the 
national directives of health policymakers [3]. In the absence of approved guidelines and 
recommendations, researchers and health economists carrying out cost-benefit analysis, 
hospital internal investigations or national reports must choose between several cost data 
sources with the risk of consciously or unconsciously biasing the results [3]. 
 Given the increasing need for and popularity of cost studies worldwide, the 
development of multiple cost databases for assessing health care costs has raised difficulty 
regarding the choice of cost data sources. Thus, in the United States, Lund et al. [4] identified 
more than 80 data sources that can be used to estimate health care costs, including data 
aggregated at the patient, hospital and national levels. However, a major difficulty in applying 
most of these databases in cost analysis lies in the fact that they were initially created and 
designed for purposes other than health care costing [5]. Moreover, each data source 
represents a unique population and has its own level of aggregation, periodicity and access 
cost, which must be considered when selecting the most appropriate data source for each 
specific research question [4].  
 Since the introduction of diagnosis-related groups (DRGs) and the deployment of 
activity pricing, European countries have developed their own hospital cost accounting 
systems as a basis for better resource management and the valuation of medical services [6]. 
The operating principle is based on the cost accounting data of a sample of hospitals at a 
national and more aggregate level to calculate hospital costs, attribute a specific cost to each 
DRG and finally make a pricing decision for the payer [7]. In this model, the initial cost 
accounting of the hospital has an important place, as its provides the first cost data for 
valuating medical services and setting their prices at the national level.  
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 In France, the health ministry has used financial incentives to encourage the 
implementation of a standardized cost accounting system in hospitals [8]. Hospital costs per 
stay are calculated using a top-down costing method combining medical and nonmedical cost 
data for each stay. Then, the overall cost of the hospital stay is broken down through specific 
indexes to evaluate each cost component [9]. Despite a few particularities, the sample of 
French hospitals that participated in the national cost study (ENC) used the same model of 
cost accounting and transferred their cost data from the hospital database to the national level 
in the ENC [10]. 
 The few studies analyzing the impact of different data sources on cost care assessment 
often compared a study group to a control group matched by sex, age, geographic location 
and other parameters [1,2]. No study has compared the hospital costs of the same patients 
using different data sources. For example, in 2016, the kidney recovery cost was assessed 
from a French hospital cost accounting system at €5,439 [11]. In a more recent publication 
based on the ENC, the kidney recovery cost was assessed at €1,432 [12]. Despite the 
increasing importance of organ recovery and the internationalization of this public health 
issue, only a few studies have focused on this problem. Given that organ recovery cost 
assessment has been sparsely investigated and that the first results issued from different data 
sources appear to differ widely, we decided to compare the costs of organ recovery 
procedures for the same patients from different cost data sources, with each representing a 
different level of data aggregation.  
 The main objective of this study was to compare a hospital cost accounting system in a 
French hospital group with the ENC in terms of the cost of organ recovery procedures. The 
secondary objective was to compare both approaches to a weighting method previously 
described [12] to assess organ recovery costs when the ENC was used. 
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Methods 
Study design 
 This study was based on discharge data on organ recovery performed in the public 
hospital group ‘Hospices Civils de Lyon’ (HCL) from January 2010 to December 2011. Direct 
medical costs were estimated from the hospital’s perspective. Direct nonmedical costs and 
indirect costs were not considered in this study. The timeframe considered was from the 
beginning until the end of the hospital stay during which organ recovery occurred. The costs 
related to family management, liquid preservation, machine perfusion and organ shipment 
were not included. 
Study population 
 All brain death donors who underwent kidney, liver, pancreas, intestine, heart, lung or 
heart-lung block recovery in the HCL between January 2010 and December 2011 were 
eligible for the analysis. To compare the costs concerning the same donors according to 
hospital cost accounting and ENC data, for the patient selection, we established an algorithm 
combining the identification code of the hospital, year of hospitalization, patient age, patient 
sex, patient DRG, and number of procedures performed. Donors were excluded if the 
algorithm of selection could not match them in both databases with certainty. Living donors 
and donors after circulatory death were also excluded. 
Cost data sources 
 The HCL cost accounting system and the 2010 and 2011 ENCs were used for this 
analysis. To respond to the second objective, weighted ENCs were also used. As hospitals 
participating in the ENC, the HCL consider the same items the ENC in the process of cost 
identification, which makes it possible to compare the valuation realized in hospital cost 
accounting at the local level with that realized in the ENC at the national level.  
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HCL cost accounting system 
 For each deceased donor whose organs were recovered during the two consecutive 
years in the HCL, a discharge abstract combining personnel and stay data was identified 
retrospectively in a local database. Cost data related to each hospital stay were collected by 
the HCL cost accounting system, which represents the first and the local source of economic 
information used for hospital management and for the economic valuation of medical 
services. 
ENC 
 The cost data collected at the national level in the ENC from a panel of public and 
private health institutions allowed us to value each hospital stay corresponding to organ 
recovery during these two consecutive years in the HCL. In contrast to hospital cost 
accounting, which addresses the original hospital stay costs, the costs collected in the ENC 
are retrieved to obtain national average costs per homogeneous groups of patients and are then 
annually published [13,14]. 
Weighted ENC 
 As organ recovery is not a procedure classified in a specific DRG, in the ENC, 
hospital stays for organ recovery may correspond to either a medical DRG or a surgical DRG, 
according to the main reason for hospital admission. As the medical DRG entails the risk of 
greatly underestimating the costs of surgical procedures, a weighting method previously 
described in the literature was applied to revalue the data from the ENCs [12]. 
Identification and quantification of cost components 
 The resources consumed during the hospital stay and the organ recovery procedure 
were identified and quantified retrospectively from the hospital discharge abstracts and 
national discharge abstract database. The eight items identified were surgery, anesthesia, 
reanimation, intensive care, ongoing monitoring, biology, imaging and medical logistics. 
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Reanimation, intensive care and ongoing monitoring are grouped into the critical care item. 
All items except medical logistics were subdivided into 5 subitems: medical staff, nonmedical 
staff, nursing staff, maintenance, depreciation and cost of block occupation. Medical logistics 
items were regrouped into sterilization, biomedical engineering, hygiene, vigilance, and 
pharmacy. 
Valuation of cost components 
 All cost components were valued in euros at 2011 prices. The items identified were 
first valued using hospital cost accounting, followed by 2010 and 2011 ENC data and then 
weighted 2010 and 2011 ENC data. All three methods use a top-down micro-costing approach 
as the costing method. Top-down micro-costing identifies all relevant hospital services at the 
most detailed level but values each hospital service per average patient [15,16]. As top-down 
micro-costing does not require patient-level data, statistical analyses of costs cannot be 
carried out, and differences between patients cannot be detected [15]. However, in France, 
organ recovery is not a procedure classified in a specific DRG. Thus, for the same organ 
recovery procedure, donors are affiliated with different groups of patients in the local 
database and with different DRGs in the national database according to different parameters. 
The variability in donor distribution facilitates statistical analyses to determine whether there 
are, for the same hospital stays, cost valuation differences among HCL cost accounting data, 
ENC data and weighted ENC data. 
 In all three cost valuation methods, each surgical procedure related or unrelated to 
organ recovery is characterized by relative cost indexes (RCIs). An RCI is used to assess the 
cost of a procedure carried out in ideal conditions [17]. These indexes are commonly used to 
break down the overall cost of surgery activities according to the number of RCIs specific to 
each procedure [18]. For each donor, we assessed a ratio corresponding to the portion of RCIs 
related to organ recovery out of the total number of RCIs related to surgical activities. Then, 
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surgery, anesthesia, biology, imaging and medical logistics were valued from the cost data 
weighted by the ratio assessed as relating exclusively to organ recovery. Regarding 
reanimation, intensive care, and ongoing monitoring, discussions with hospital coordinators 
of organ and tissue procurement allowed us to elaborate the working hypothesis that 
expenditures related to organ recovery are exclusively focused on the last day of the hospital 
stay. Thus, reanimation, intensive care, and ongoing monitoring were valued from the cost 
data weighted by the length of stay corresponding to each donor. The organ recovery 
procedure was assessed with the same approach to reveal the cost differences among the 
hospital cost accounting, ENC and weighted ENC data.  
Analyses 
 Three cost evaluations were conducted, with each exploring a specific characteristic of 
organ recovery procedures. All costs are presented according to their mean and standard 
deviation (SD).  
• The cost of hospital stays during which an organ recovery procedure was performed 
was obtained for an overview of hospital costs related to organ recovery activity 
• The cost of organ recovery procedures was obtained to assess the portion of hospital 
stay costs related exclusively to organ recovery activities. 
• The costs of the eight items identified were also specified to identify whether the cost 
of one or more items differ more widely among the data sources. 
 A Kruskal-Wallis test was used to detect whether at least two of the cost databases 
provide different results. Then, a Mann-Whitney test was used to compare the three cost 
databases with each other. 
Results 
 From January 2010 to December 2011, 103 and 101 brain death donors were 
identified in the local and national databases, respectively. The selection algorithm matched 
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88 of them to include in the analysis, corresponding to a total of 201 organs recovered (Table 
1). 
 The Kruskal-Wallis test highlighted differences among the three cost data sources 
regarding the cost of hospital stays, the cost of organ recovery and all items of the organ 
recovery procedure except imaging (Table 2). Thus, a Mann-Whitney test was applied to 
compare the three cost databases in terms of all costs except imaging costs (Table 2).  
Comparison of hospital cost accounting valuation with ENC assessment 
 The costs assessed using hospital cost accounting differ significantly from those 
assessed using ENC data (Mann-Whitney; P-value < 0.001). 
 Using hospital cost accounting, the mean costs for hospital stays, recovery procedure, 
surgery, anesthesia, critical care, biology and logistics were assessed as €12,074 (SD €6 956), 
€4,311 (SD €1,738), €1 080 (SD €573), €975 (SD €494), €1 202 (SD €705), €453 (SD €616), 
and €415 (SD €202), respectively (Table 2). 
 Using the ENC as the data source, the costs assessed for the same donors and the 
same items were significantly lower, and the SD increased considerably (Mann-Whitney; P-
value < 0.001). The mean costs for hospital stays, recovery procedure, surgery, anesthesia, 
critical care, biology and logistics were assessed as €4,961 (SD €7,295), €862 (SD €887), 
€112 (SD €198), €91 (SD €142), €350 (SD €447), €116 (SD €117), and €86 (SD €110), 
respectively (Table 2). 
Comparison of weighted ENC assessment with ENC and hospital cost accounting valuation 
 The data revaluation of the weighted ENC exclusively concerned the surgery and 
anesthesia items, as previously described and published [12]. This revaluation decreased the 
gap between the cost assessment based on hospital cost accounting and the cost assessment 
based on the original ENC data. Nevertheless, the cost assessment based on the weighted 
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ENC remains significantly lower than the assessment based on hospital cost accounting data, 
regardless of the cost evaluation made (Mann-Whitney; P-value < 0.001) (Table 2). 
 No difference for critical care, biology and logistics was observed between the 
assessment based on the weighted ENC and the original ENC, as the revaluation method does 
not concern these items (Table 2). 
Discussion 
 In France, the standardization policies for hospital cost accounting and the ENC made 
it possible to compare, item by item, hospital costs related to organ recovery from different 
levels of data aggregation. The implementation of a selection algorithm combining patient 
parameters could facilitate this comparison of the same patients and the same hospital stays. 
Using the ENC, the mean costs for hospital stays and organ recovery procedures were 
assessed as €4,961 (SD €7,295) and €862 (SD €887), respectively, versus €12,074 (SD 
€6,956) and €4,311 (SD €1,738) for the hospital cost accounting assessment. The use of the 
ENC seems to underestimate the cost valuation compared to valuation by hospital cost 
accounting. The use of the weighted ENC methodology described to better reflect organ 
recovery cost decreases the differences between hospital cost accounting and the ENC. 
Despite the use of this weighting method, cost differences remain among the three data 
sources. 
 As the first economic evaluation conducted in France to compare several cost data 
sources, this study highlights the cost differences existing between hospital cost accounting 
and the French ENC. These differences relativize and lend caution to the interpretation of the 
results of our previous study assessing organ recovery cost from ENC data [12]. More 
generally, the current findings question the use of the ENC as a reference for economic 
evaluation. For some authors, the multiple and complex retreatment steps prevent the ENC 
from fulfilling its first mission, which is to give a national mean cost for hospital services 
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[19]. Currently, the ENC data may be used more to reflect a distribution of a global healthcare 
budget across the different DRGs and may not reflect real hospital costs based on hospital 
cost accounting [19]. Nevertheless, the ENC data remain important and widely used, and the 
economic information based on the ENC facilitates the resource management of healthcare 
providers without their own cost accounting system [20]. 
 Most authors agree that there is not a perfect cost database that can be used for all 
research questions. Many of the currently available data sources, including administrative 
sources, have not been designed for medico-economic assessment [21]. In the absence of 
guidelines, the authors recommend choosing the data source according to the study purpose 
and timing [21]. The strengths and weakness of the data source chosen should be kept in mind 
and clearly debated. Only a few studies have tested the impact of the data source on cost 
assessment. The case of colorectal cancer strengthens our results. In fact, Yabroff et al. [1] 
showed that the mean net annual per person cost varies significantly, from $5,341 to $11,614, 
according to the data source chosen. They affirmed that there is no gold standard data source 
for estimating the prevalence costs of cancer care. In 2009, Lund et al. [4] showed that among 
the 88 data sources referenced in the US, there are different levels of data aggregation: 
patient, service, hospital, and national. Depending on the level of aggregation, some cost 
elements will or will not be included in the cost identification and cost valuation processes, 
which may influence the results of cost analyses [4]. 
 Zeynep Or demonstrates that the type of establishment influences the hospital stay cost 
[22]. She notes that in most situations, there is an additional cost of care in university hospital 
centers. As one such center, the HCL is particularly exposed to these additional costs. These 
additional costs reflect the specific characteristics of university hospital centers that include 
research and teaching activities. The absence of patient selection and the admission of more 
serious cases into these institutions also impact the university hospital stay cost [23,24]. In 
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fact, patients are not randomly distributed among hospitals, and some hospitals receive 
consistently more patients associated with higher costs for the same DRG [25]. The French 
ENC includes different types of establishments: private, public, and nonprofit institutions. 
This approach can explain the differences observed between valuation based on the HCL's 
cost accounting and that based on ENC data. 
 Some limitations of our work should be noted. Although the number of hospital stays 
was limited to the cases of a single public institution, the HCL was chosen for its several 
years of regular participation in the ENC, which reflects its engagement in data collection. 
The extension of this comparative study to other hospitals and a longer observation period 
would strengthen our results concerning the status of the ENC as a cost referential. Another 
limitation concerns the costing methods used in the hospital cost accounting system and ENC. 
Although bottom-up micro-costing is known to be the best way to assess hospital cost, all 
databases analyzed in our study used a top-down micro-costing approach. The latter method is 
certainly less accurate than bottom-up micro-costing, but it is more easily applicable and more 
developed in other countries in view of future comparisons [6]. The last important limitation 
concerns the consideration or lack of consideration of all hospital cost accounting data in the 
mean cost calculation of each DRG. As shown in our previous publication, three-quarters of 
the hospital stays for organ recovery are classified in a medical DRG according to the main 
cause of hospital admission. The methodology of the ENC for calculating the mean cost of 
each DRG excludes the extreme values. Due to the surgical procedure, a hospital stay during 
which organ recovery occurs is often more expensive than a conventional medical DRG; it is 
thus more likely to represent an extreme value and ultimately to be excluded from the 
calculation of the mean cost of the DRG in which the hospital stay is classified. 
 The generalization of this comparative study to other establishments participating in 
the ENC is easily achievable if the institutions comply with the common methodology 
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recommended for their cost accounting. Such an effort would strengthen our results and 
ensure that they are not tied to the HCL. Generalization to other types of stays would ensure 
that the differences found are not related to the organ recovery procedure but rather to the use 
of cost data sources with different levels of aggregation. In many developed countries, 
reference hospitals collect cost data that are then reassembled at a higher level of aggregation 
within a national database [9]. The generalization of the findings of this comparative study to 
other countries would make it possible to study the representativeness of national databases 
compared to local databases. 
Conclusions 
 The choice of cost data sources is a challenge common to all countries wishing to 
carry out quality medico-economic assessments. Due to the growing number of available 
databases, this choice is increasingly complex. Researchers are waiting for clear 
recommendations allowing a choice between different sources of data and thus facilitating 
comparisons between future national and international studies. Meanwhile, it is fundamental 
for readers, hospital managers and decision-makers to know the strengths and weaknesses of 
each database used to be able to interpret the results in an informed context. 
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Table 1. Deceased donor characteristics and practices between January 2010 and December 
2011 in the HCL. 
  Donors Age Number of organs recovered simultaneously  Organs/donor 
                  
      1 2 3 4 5 > 5   
                    
2010 54 52 17 19 9 7 2 0 2.22 
                    
2011 34 48 10 10 9 1 4 0 2.38 
                    
Total  88 51 27 29 18 8 6 0 2.28 
 
 
Table 2. Organ recovery cost assessment using different cost data sources in the HCL 
between 2010 and 2011 (2011 euros). 
  
(1) Hospital Cost 
Accounting  
 
 
(2) National 
Cost Study 
 
 
   (3) Weighted 
National Cost 
Study 
 
Kruskal-
Wallis 
 
 
                Mann-Whitney 
 
 
 
  Mean (SD) Mean (SD) Mean (SD) P-value   1-2   1-3   2-3
                
Hospital 
stays 12,074 (6,956) 4,961 (7,295) 4,961 (7,295) < 0.001 < 0.001 < 0.001 1 
                
Recovery 
procedure 4,313 (1 738) 862 (887) 1,490 (753) < 0.001 < 0.001 < 0.001 
< 
0.001
                
Surgery 1,080 (573) 112 (198) 468 (146) < 0.001 < 0.001 < 0.001 
< 
0.001
                
Anesthesia 975 (494) 91 (142) 362 (111) < 0.001 < 0.001 < 0.001 
< 
0.001
                
Critical care  1,202 (705) 350 (447) 350 (447) < 0.001 < 0.001 < 0.001 1 
                
Imaging   188 (275) 108 (98) 108 (98) 0.671 NA NA NA 
                
Biology 453 (616) 116 (117) 116 (117) < 0.001 < 0.001 < 0.001 1 
                
Logistics 415 (202) 86 (110) 86 (110) < 0.001 < 0.001 < 0.001 1 
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